Changes in exercise endurance and inspiratory capacity after lumacaftor/ivacaftor therapy in cystic fibrosis
Open Access
- 30 July 2023
- journal article
- letter
- Published by Taylor & Francis in Pulmonology
- Vol. 29 (4) , 338-341
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosisRespiratory Research, 2020
- Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosisJournal of Cystic Fibrosis, 2019
- Use of exercise testing in the evaluation of interventional efficacy: an official ERS statementEuropean Respiratory Journal, 2016
- Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPDPulmonary Medicine, 2013
- The Prognostic Value of Exercise Testing in Patients with Cystic FibrosisNew England Journal of Medicine, 1992
- Psychophysical bases of perceived exertionMedicine & Science in Sports & Exercise, 1982